Showing results (1-10 of 102) with videos related to
Sort By:
Pageof 11
Connecticut Medicine|December 4, 2015
Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 MutationNataliya Mar, James J VredenburghConnecticut Medicine|May 22, 2018
Kikuchi-Fujimoto Disease in aYoung African American Male: Are we Seeing a Paradigm Shift in Disease Epidemiology? A Case ReportVinay Rao, Frank Bauer, James J VredenburghClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2015
CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the LimitationsNataliya Mar, Annick Desjardins, James J VredenburghConnecticut Medicine|May 18, 2018
Refractory Small Cell Carcinoma of the Ovary - Hypercalcemic Type (SCCOHT) Treated with Romidepsin and Topotecan: A Case Report and Review of the LiteratureVinay Rao, Frank Bauer, James J VredenburghClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2022
Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of TreatmentsGonca Ozcan, Meghana Singh, James J VredenburghCase Reports in Oncology|May 3, 2019
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated MeningiomaVinay Mathew Thomas, Poorva Bindal, James J VredenburghBiologics : Targets & Therapy|August 27, 2009
Current available therapies and future directions in the treatment of malignant gliomasAnnick Desjardins, David A Reardon, James J VredenburghLung Cancer (Amsterdam, Netherlands)|January 21, 2015
Targeting HER2 in the treatment of non-small cell lung cancerNataliya Mar, James J Vredenburgh, Jeffrey S WasserCase Reports in Oncology|August 27, 2010
Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case ReportKatherine B Peters, Roger McLendon, Michael A Morse, et al.Current Treatment Options in Oncology|February 8, 2008
The emerging role of anti-angiogenic therapy for malignant gliomaDavid A Reardon, Annick Desjardins, Jeremy N Rich, et al.Pageof 11